Follow The Filings

NVNO enVVeno Medical

enVVeno Medical earnings company data as of 4:45 AM ET 10/29

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 30 Oct EPS -3.27 — —
Rev — — —

Insider trades

Open-market buys and sales by NVNO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NVNO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $4,922 sold by 1 insider under 10b5-1 plans
  1. Francis Duhay Director
    Planned sale
    $123 11 shares at $11.21 0.5% of stake
    Traded Sep 11 Filed Sep 14
  2. Francis Duhay Director
    Planned sale
    $1,443 140 shares at $10.31 5.6% of stake
    Traded Jun 11 Filed Jun 12
  3. Francis Duhay Director
    Planned sale
    $1,613 140 shares at $11.52 5.3% of stake
    Traded Mar 12 Filed Mar 13
  4. Francis Duhay Director
    Planned sale
    $1,742 4,900 shares at $0.3600 5% of stake
    Traded Dec 11, 2025 Filed Dec 12, 2025

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13D/A —
SCHEDULE 13G/A —
10-Q
8-K 7.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,7.01,8.01,9.01
10-K
SCHEDULE 13D —
SCHEDULE 13D —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —
8-K 2.02,8.01,9.01
8-K 5.03,9.01
8-K 5.07,9.01
8-K 5.03,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 7.01,9.01
DEF 14A
10-Q
DEFA14A
424B5

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.